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Abstract
Introduction: Nephrogenic systemic fibrosis is a condition that has recently been recognized in patients with
chronic renal disease and is associated with use of gadolinium-based contrast agents of ubiquitous use in
magnetic resonance imaging scans. The condition is believed to arise through inadequate renal clearance of the
gadolinium-based contrast agents, resulting in bodily deposition of the gadolinium; this is most widely recognized
in the skin, but also occurs in other tissues.
Case presentation: We report the case of a 52-year-old Caucasian man with hypothyroidism and chronic renal
disease who developed nephrogenic systemic fibrosis upon repeated exposure to gadolinium, and who presented
with a subsequent malabsorption of levothyroxine. This malabsorption resolved only partially upon amelioration of
other conditions that might contribute to malabsorption, including edema and infectious diarrhea. The presence of
gadolinium was quantified in specimens from his gastrointestinal tract. Our patient otherwise demonstrated
adequate gastrointestinal nutritive absorption, objectively shown by normal albumin levels, resolution of diarrhea,
and maintenance of his bodily weight.
Conclusions: Our observations suggest that nephrogenic systemic fibrosis can also affect tissue of the
gastrointestinal tract, potentially contributing to partial malabsorption of levothyroxine in patients with
hypothyroidism.
Introduction
Nephrogenic sclerosing fibrosis (NSF), also known as
nephrogenic sclerosing dermopathy, is characterized as
thickening and hardening of the skin overlying extremi-
ties and trunk secondary to fibrosis of the dermis in
patients with renal failure [1,2]. The condition was first
described by Cowper et al. as an idiopathic cutaneous
fibrosing disorder or scleromyxedema-like illness in
patients on dialysis in whom transplantation had been
unsuccessful [3]. Other than end-stage renal disease
(ESRD) patients on dialysis, patients with hepatorenal
syndrome (HRS), recent vascular surgery, recent venous
thromboembolic events, and those with an estimated
glomerular filtration rate (GFR) < 30 ml/minute/1.73 m
2
appear at greatest risk for developing NSF [4,5]. NSF
was initially believed to be limited to the skin, but
recent reports, including autopsies, have identified invol-
vement of skeletal muscle, myocardium, lungs, and kid-
neys, indicating the systemic nature of this disease
[2,6,7].
Case presentation
A 52-year-old Caucasian man with chronic kidney dis-
ease (CKD) was admitted to our university hospital from
a skilled nursing facility with generalized edema, woody
thickening of his skin, and bilateral hand contractures
after recurrent hospitalizations during which time he
underwent multiple MRI scans with gadolinium-based
contrast agents (GBCA). Our patient’sm e d i c a lh i s t o r y
was significant for type 2 diabetes mellitus, hypertension,
CKD secondary to diabetic nephropathy, hypothyroidism,
congestive heart failure, and hemochromatosis. Upon
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Hagedorn (NPH) insulin 15 units twice daily, levothyrox-
ine (LT4) 75 μg once daily, clonidine 0.1 mg twice daily,
metoprolol sustained-release 25 mg once daily, amlodi-
pine 5 mg once daily, enteric-coated aspirin 325 mg
daily, and calcitriol 0.5 μg once daily.
In the four months prior to this admission, he was
first admitted for aspiration pneumonia and had a pro-
longed hospital course. He was started with ceftriaxone
and metronidazole, later changed to piperacillin/tazo-
bactam and levofloxacin for broader coverage. His base-
line creatinine level was 3.5 mg/dL and he had a
glomerular filtration rate (eGFR) of 24 mL/minute.
Shortly after admission, he developed acute kidney fail-
ure (ARF). Acute tubular necrosis (ATN) and increased
creatinine was attributed to episodes of hypotension.
Over the course of several days, his creatinine level sta-
bilized to a range between 4.0 and 4.5 mg/dL. His hos-
pital course was then complicated by bloody diarrhea,
prompting several gastrointestinal studies. A computed
tomography (CT) scan of his abdomen revealed a diffu-
sely fluid-filled colon with colitis. Flexible sigmoidoscopy
showed acute and chronic inflammation with biopsy
results consistent with ischemic colitis. Thereafter, he
underwent magnetic resonance angiography (MRA) and
MRI with gadolinium of the abdomen to evaluate for
mesenteric vein thrombosis. These tests returned nega-
tive results. Our patient was subsequently treated with
total parenteral nutrition (TPN) for bowel rest and his
symptoms resolved.
Subsequently, our patient developed fungemia. An
abdominal MRI scan with gadolinium revealed no
abscess. At this time, his creatinine level increased to
6.6 mg/dL and his glomerular filtration rate (eGFR)
decreased to 9 mL/minute. Our patient was treated for
presumptive recurrent ischemic colitis without perfora-
tion and was continued on a prolonged course of TPN
for bowel rest. His symptoms improved and he was dis-
charged to a skilled nursing facility.
Shortly after his discharge, he was readmitted with new
right-sided weakness and underwent an MRI scan with
GBCA that revealed a left thalamic cerebrovascular acci-
dent, from which he recovered quickly. A new physical
finding revealed skin with a diffuse woody peau d’orange
appearance with tightening of the palmar fascia bilater-
ally at both hands with all fingers slightly drawn in. His
neurological examination results were unremarkable. His
admission thyroid stimulating hormone (TSH) level was
11.21 mU/L with a free thyroxine level (T4) of 0.7 ng/dL
while on 75 μg of levothyroxine (LT4) (Figure 1).
A skin biopsy was performed for evaluation of the
hand contractures. The histology revealed numerous
dermal fibroblast-like cells with dermal mucin deposi-
tion, consistent with NSF. Two weeks later, thyroid
studies revealed a serum TSH rise to 117.5 mU/L and
free T4 drop to 0.4 ng/dL. His LT4 dose was increased
from 75 to 100 μg daily. Our patient was observed by
nursing staff for his medication compliance.
Because of the possibility of LT4 malabsorption, our
patient underwent an oral LT4 loading test (Figure 2).
The protocol for this test entailed obtaining baseline
total T4, TSH, and free T4 levels, followed by administra-
t i o no fas i n g l eo r a ld o s eo fL T 41 0 0 0μg, with repeat
total T4 measured at two hours, and again at four hours
after LT4 administration [8]. Baseline laboratory tests
showed a total TSH level of 110.6 mU/L, free T4 level of
< 0.3 ng/dL and total T4 level of 1.8 ng/dL. The challenge
test revealed a failure of total T4 to rise, with values of
1.7 ng/dL at two hours and 1.8 ng/dL at four hours, con-
sistent with LT4 malabsorption. His LT4 malabsorption
was suspected to be partly secondary to NSF caused by
exposure to gadolinium from the multiple MRI scans.
Our patient was started on intravenous LT4 with
some improvement of symptoms. The results of repeat
laboratory testing four days later revealed a decline in
TSH of 61.95 mU/L and rise in total T4 to 4.4 ng/dL.
He was discharged on intra-muscular LT4 100 μg daily.
However, two months later, our patient was seen at an
outside community hospital for treatment of a urinary
tract infection (UTI) and was switched back to oral LT4
upon discharge. Testing one month later showed a
recurrent rise in TSH to 104.83 mU/L, and our patient
was restarted on intra-muscular LT4 at a dose of 100 μg
daily. His pharmacy was contacted to ensure compliance
with the prescribed refill. Repeat laboratory tests results
from two months later showed modest improvements,
with a TSH of 39.82 mU/L. Based on these results, his
intra-muscular LT4 was increased to 120 μg daily.
Of note, during clinical follow-up, our patient did not
appear to have malabsorption of other nutrients. His
albumin rose over time from 2.5 g/dL on initial admis-
sion up to 3.7 g/dL 10 months later. Also, his diarrhea
did not recur, and he maintained his weight.
Four years ago, because of a nationwide shortage of
intra-muscular LT4, a decision was made to repeat the
oral loading LT4 test to help assess whether bowel
edema, as a complication of hypothyroidism, had been
the primary etiological factor in the malabsorption of
LT4. The results of this test showed a total T4 level of
3.9 ng/dL, which rose to a value of 6.1 ng/dL for both
the two-hour and four-hour time intervals. With this
small, but demonstrable, amount of oral LT4 absorption,
a decision was made to do a retrial of oral LT4, starting
a tad o s eo f9 0 0μg daily. Based on repeat laboratory
analysis, his LT4 dose was gradually decreased to a
maintenance dose of 400 μg daily. He maintained his
TSH on oral LT4 for the next year until his death sec-
ondary to sudden cardiac arrest.
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nephrogenic fibrosing dermopathy as a contributing fac-
tor in this partial malabsorption, gadolinium quantifica-
tion was performed on gastrointestinal specimens at the
laboratory of one of the authors (WAH). This analysis
revealed 154.0 parts per million (PPM) in the skin, 22.8
PPM in the colon, and 7.0 PPM in the ileum/cecum/
colonic specimens with all appropriate positive and
negative control tissue blanks functioning (Figure 3).
Discussion
To the best of our knowledge, this case presentation is
the first to describe a gastrointestinal involvement of
NSF that appeared to result in uncontrolled hypothyr-
oidism secondary to malabsorption of oral LT4. Of par-
ticular interest, our patient did not appear to have
malabsorption of other oral medications. LT4 is known
to be predominantly absorbed in the small intestine,
specifically the jejunum and ileum. Ischemic colitis,
infectious diarrhea and use of TPN during his hospitali-
zation, along with the presence of diffuse bowel edema,
may have each contributed to poor absorption of this
medication. However, in such circumstances, one would
expect the malabsorption to resolve with improvement
in each of these conditions; in our patient’s case, malab-
sorption persisted despite resolution of these other com-
plicating conditions.
The issue of potential bowel edema contributing to
malabsorption was addressed by utilizing an intra-mus-
cular formulation of LT4, to allow for attainment of a
euthyroid state. However, repeat oral loading LT4 test-
ing demonstrated that our patient remained consider-
ably resistant to absorption, despite achieving
normalized TSH levels and resolution of visible bodily
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Figure 1 Change in serum TSH as a function of the time from our patient’s initial hospitalization. Light blue boxes above graph, oral
levothyroxine with coincident doses noted by markings on upper right. Dark blue boxes above graph, intra-muscular levothyroxine with
coincident doses noted by markings on upper right. Black arrows in left bottom corner, dates of MRI scans with the gadolinium contrast. Inset
graph illustrates magnified view of TSH trend after restarting oral levothyroxine treatment. IM, intra-muscular; TSH, thyroid stimulating hormone;
Tx, treatment.
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eration that NSF might have intestinal mucosa involve-
m e n t .T h i st h e o r yi ss u p p o r t e db yt h ep r e s e n c eo f
demonstrable gadolinium in gastrointestinal biopsies,
along with his continued need for supratherapeutic
doses of LT4 to maintain a euthyroid state. However, it
is critical to note that the presence of gadolinium in the
tissue does not necessarily imply pathogenicity, particu-
larly as the gastrointestinal specimen did not show any
other significant pathology. Admittedly, there is limited
data on gadolinium levels in bodily tissues of patients
with NSF. Disturbances in LT4 absorption have been
reported with co-administration of calcium carbonate,
ferrous sulfate, aluminum hydroxide, chromium picoli-
nate and magnesium, prompting speculation that other
divalent and trivalent metal ions could interfere with
absorption [9-12]. It is unclear but certainly worthy of
speculation that gadolinium, being a trivalent ion, could
interfere with thyroxine absorption, but it is further
speculative as to whether this would be a persistent
anomaly, considering that gadolinium so deposited in
tissue most likely exists as precipitated gadolinium phos-
phate [13]. These are intriguing avenues for future
exploration.
NSF has been described in various organs, including
the myocardium, lungs, kidneys, testes and dura mater
[2,6,7]. There are several hypotheses regarding the
pathogenesis of NSF. Some investigators assert that
transforming growth factor b is involved in the patho-
genesis of NSF [6]. In vitro studies have shown that
transforming growth factor b1 has the potential to
induce fibrocyte differentiation and to promote expres-
sion of fibrocyte collagen I, which deposits in the cells
to cause fibrosis [14].
The US Food and Drug Administration (FDA) first
notified health care professionals and the public about
the gadolinium-related risks for NSF five years ago.
GBCAs are commonly used to improve visualization of
structures when patients undergo an MRI or MRA pro-
cedure. Five gadolinium-based contrast agents were
approved for use in the US at the time of this report,
and include: Magnevist (gadopentetate dimeglumine),
Ominiscan (gadodiamide), OptiMARK (gadoverseta-
mide), MultiHance (gadobenate dimeglumine), and Pro-
hance (gadoteridol). When a specific agent was
identified, Omniscan (the gadolinium agent used in our
patient) was the most often implicated in NSF, followed
by Magnevist and OptiMARK. Approximately three
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Figure 2 Change in total thyroxine as a function of time during the oral levothyroxine loading tests. Red diamonds with dashed line,
loading test 1; blue squares with solid line, loading test 2.
Aggarwal et al. Journal of Medical Case Reports 2011, 5:566
http://www.jmedicalcasereports.com/content/5/1/566
Page 4 of 6years ago, a sixth agent, Vasovist (gadofosveset triso-
dium), was approved by the FDA for use in MRA.
T h e r ei sn oc o n s i s t e n t l ye f f e c t i v et r e a t m e n tf o rN S F ,
although improvement has been reported with plasma-
pheresis, and in most reported cases, the disease appears
to correspond to the improvement in underlying renal
function [15].
Conclusions
As general internists and endocrinologists continue to
care for more patients with chronic kidney disease and
hypothyroidism, it is prudent that physicians recognize
any emerging disorders in these patients, including any
untoward complications associated with NSF. Continued
observation and additional reporting will be necessary to
ascertain if NSF, with deposition of gadolinium in the
bowel, results in malabsorption of LT4 or other medica-
tions, and what mechanism of malabsorption may be
involved in this phenomenon.
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